登录

RivaMed Receives ¥100M Series B Financing, Providing IoT Solutions of Smart Hospitals

作者: Mailman 2021-01-22 09:28
瑞华康源
http://www.rivamed.cn/
企业数据由 动脉橙 提供支持
医院智能物联网解决方案提供商 | B轮 | 运营中
中国-浙江
2021-01-20
融资金额:数亿人民币
国投创业
查看

(VCBeat) Jan. 20, 2021 -- In January 2021, Zhejiang Ruihua Kangyuan Technology Co., Ltd. ("RivaMed") announced the closing of a Series B financing of hundreds of millions, led by SDIC Venture Capital, with participation from China Creation Ventures, Delta Capital, and the existing investor IN Capital. 


The funds are earmarked for the product development of RivaMed’s smart hospital solution, the construction of the Internet of Things (IoT) platform, as well as the business expansion of AI and IoT management software.


RivaMed is a developer of healthcare IoT solutions, focusing on pharmacy automation and intelligent logistics & supply chain management. Products include smart management cabinets, medical robots, delivery management, software products, and more. The company aims to reduce the uneven distribution of medical resources, improve medical staff efficiency, reduce medical errors, improve medical quality, and increase operational management efficiency.


RivaMed provides an overall solution from IoT, platformization, big data to intellectualization for smart hospital construction, covering the scenario of smart management, smart medical treatment, and smart services. 


Relying on the solutions close to the clinical needs and optimizing the operation efficiency of medical institutions, RivaMed has been deeply engaged in the construction of smart hospitals, occupying 80% of the market share among the Top100 hospitals in China, and more than 40% of the market share among the Top100 medical institutions.


>>>>

About SDIC Venture Capital


Founded in 2016, SDIC Venture Capital is a fund management company founded by the State Development and Investment Corp. (SDIC), under a market-driven governance structure. SDICVC currently manages four funds, with AUM at 14 billion yuan.


>>>>

About China Creation Ventures (CCV)


CCV was founded by the former KPCB China Managing Partner, Wei Zhou, and his TMT investment team of many years in KPCB China. With the majority of members from KPCB China, CCV has developed deep domain expertise and insight in the TMT industry. The companies they invested at the early stage include JD.com (NASDAQ:JD), CreditEase (NYSE:YRD), Rong360 (NYSE:JT), and so on.

相关赛道 医疗信息化
注:文中如果涉及企业数据,均由受访者向分析师提供并确认。
声明:动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。转载请联系tg@vcbeat.net。

Mailman

医疗行业观察者

分享
动脉橙
以上数据来自动脉橙产业智库

我们以独创的在线数据库方式,为健康产业人士提供全方位和实时的市场资讯、行业数据和分析师见解。现已覆盖数字健康、医疗器械、生物医药等近500+细分赛道,涉及公司名单、招投标、投融资信息、头部企业动态等各类数据并持续更新。

点击 【申请试用】了解动脉橙产业智库更多内容。
精彩内容推荐

专注智慧医疗领域,联新完成3亿元战略融资

Lachesis Snares ¥150M in Series B+ round

《2022数字医疗年度创新白皮书》发布,三大领域五大热点全面讲述数字医疗“中国故事”

京颐科技李志:在医疗IT行业中等风来【隆门资本投资案例】

Mailman

共发表文章3245篇

最近内容
  • 知之甚少:调研885名投资人后,原来美国VC们这样做决策

    2023-03-20

  • 辉瑞想要收购Seagen只是开始,这才是2023年并购的两大趋势

    2023-03-05

  • 【融资】核药企业Ratio再融资2000万美元,和拜耳合作研究新前列腺癌放射性疗法

    2023-02-09

上一篇

Matridx Closes ¥200 Miilion Series B Financing, Focusing on Precision Diagnotics of Infection

2021-01-22
下一篇

Fangzi Technology Raises ¥10M in Series Pre-A Funding Round

2021-01-22